Guardant Health Launches Liquid Biopsy Test For Detecting Colorectal Cancer Recurrence

Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.

Liquid biopsy

Guardant Health’s CEO Helmy Eltoukhy expects the launch of the company’s new liquid biopsy test, indicated for detecting early-stage colorectal cancer, will be a “big game changer.” 

The new liquid biopsy test, Guardant Reveal, is a plasma-only circulating tumor DNA (ctDNA) test indicated for detecting residual and...

More from R&D

More from Business